nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Discomfort—Cisplatin—testicular cancer	0.00214	0.00214	CcSEcCtD
Doxylamine—Affect lability—Epirubicin—testicular cancer	0.00214	0.00214	CcSEcCtD
Doxylamine—Vomiting—Vinblastine—testicular cancer	0.00212	0.00212	CcSEcCtD
Doxylamine—Malaise—Etoposide—testicular cancer	0.0021	0.0021	CcSEcCtD
Doxylamine—Breast disorder—Methotrexate—testicular cancer	0.0021	0.0021	CcSEcCtD
Doxylamine—Vertigo—Etoposide—testicular cancer	0.0021	0.0021	CcSEcCtD
Doxylamine—Decreased appetite—Ifosfamide—testicular cancer	0.0021	0.0021	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.00209	0.00209	CcSEcCtD
Doxylamine—Leukopenia—Etoposide—testicular cancer	0.00209	0.00209	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00208	0.00208	CcSEcCtD
Doxylamine—Fatigue—Ifosfamide—testicular cancer	0.00208	0.00208	CcSEcCtD
Doxylamine—Anaphylactic shock—Cisplatin—testicular cancer	0.00208	0.00208	CcSEcCtD
Doxylamine—Hypersensitivity—Bleomycin—testicular cancer	0.00208	0.00208	CcSEcCtD
Doxylamine—Constipation—Ifosfamide—testicular cancer	0.00206	0.00206	CcSEcCtD
Doxylamine—Mood swings—Epirubicin—testicular cancer	0.00206	0.00206	CcSEcCtD
Doxylamine—Nervous system disorder—Cisplatin—testicular cancer	0.00204	0.00204	CcSEcCtD
Doxylamine—Thrombocytopenia—Cisplatin—testicular cancer	0.00204	0.00204	CcSEcCtD
Doxylamine—Tachycardia—Cisplatin—testicular cancer	0.00203	0.00203	CcSEcCtD
Doxylamine—Asthenia—Bleomycin—testicular cancer	0.00202	0.00202	CcSEcCtD
Doxylamine—Convulsion—Etoposide—testicular cancer	0.00202	0.00202	CcSEcCtD
Doxylamine—Dehydration—Epirubicin—testicular cancer	0.00202	0.00202	CcSEcCtD
Doxylamine—Diplopia—Doxorubicin—testicular cancer	0.00201	0.00201	CcSEcCtD
Doxylamine—Hyperhidrosis—Cisplatin—testicular cancer	0.00201	0.00201	CcSEcCtD
Doxylamine—Pruritus—Bleomycin—testicular cancer	0.002	0.002	CcSEcCtD
Doxylamine—Feeling abnormal—Ifosfamide—testicular cancer	0.00199	0.00199	CcSEcCtD
Doxylamine—Nausea—Vinblastine—testicular cancer	0.00198	0.00198	CcSEcCtD
Doxylamine—Orthostatic hypotension—Epirubicin—testicular cancer	0.00198	0.00198	CcSEcCtD
Doxylamine—Anorexia—Cisplatin—testicular cancer	0.00198	0.00198	CcSEcCtD
Doxylamine—Affect lability—Doxorubicin—testicular cancer	0.00198	0.00198	CcSEcCtD
Doxylamine—Pancreatitis—Methotrexate—testicular cancer	0.00197	0.00197	CcSEcCtD
Doxylamine—Discomfort—Etoposide—testicular cancer	0.00196	0.00196	CcSEcCtD
Doxylamine—Breast disorder—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Doxylamine—Hypotension—Cisplatin—testicular cancer	0.00194	0.00194	CcSEcCtD
Doxylamine—Nasopharyngitis—Epirubicin—testicular cancer	0.00194	0.00194	CcSEcCtD
Doxylamine—Hypersensitivity—Dactinomycin—testicular cancer	0.00194	0.00194	CcSEcCtD
Doxylamine—Abdominal discomfort—Methotrexate—testicular cancer	0.00192	0.00192	CcSEcCtD
Doxylamine—Confusional state—Etoposide—testicular cancer	0.00192	0.00192	CcSEcCtD
Doxylamine—Urticaria—Ifosfamide—testicular cancer	0.00192	0.00192	CcSEcCtD
Doxylamine—Pancytopenia—Methotrexate—testicular cancer	0.00191	0.00191	CcSEcCtD
Doxylamine—Anaphylactic shock—Etoposide—testicular cancer	0.0019	0.0019	CcSEcCtD
Doxylamine—Mood swings—Doxorubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Doxylamine—Asthenia—Dactinomycin—testicular cancer	0.00189	0.00189	CcSEcCtD
Doxylamine—Dehydration—Doxorubicin—testicular cancer	0.00187	0.00187	CcSEcCtD
Doxylamine—Thrombocytopenia—Etoposide—testicular cancer	0.00187	0.00187	CcSEcCtD
Doxylamine—Tachycardia—Etoposide—testicular cancer	0.00186	0.00186	CcSEcCtD
Doxylamine—Dyspnoea—Cisplatin—testicular cancer	0.00185	0.00185	CcSEcCtD
Doxylamine—Hyperhidrosis—Etoposide—testicular cancer	0.00184	0.00184	CcSEcCtD
Doxylamine—Pancreatitis—Epirubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Doxylamine—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Doxylamine—Breast disorder—Doxorubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Doxylamine—Anorexia—Etoposide—testicular cancer	0.00182	0.00182	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Doxylamine—Decreased appetite—Cisplatin—testicular cancer	0.00181	0.00181	CcSEcCtD
Doxylamine—Diarrhoea—Dactinomycin—testicular cancer	0.0018	0.0018	CcSEcCtD
Doxylamine—Nasopharyngitis—Doxorubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.0018	0.0018	CcSEcCtD
Doxylamine—Vomiting—Bleomycin—testicular cancer	0.00179	0.00179	CcSEcCtD
Doxylamine—Drowsiness—Methotrexate—testicular cancer	0.00179	0.00179	CcSEcCtD
Doxylamine—Depression—Methotrexate—testicular cancer	0.00178	0.00178	CcSEcCtD
Doxylamine—Pancytopenia—Epirubicin—testicular cancer	0.00178	0.00178	CcSEcCtD
Doxylamine—Hypotension—Etoposide—testicular cancer	0.00178	0.00178	CcSEcCtD
Doxylamine—Rash—Bleomycin—testicular cancer	0.00178	0.00178	CcSEcCtD
Doxylamine—Dermatitis—Bleomycin—testicular cancer	0.00178	0.00178	CcSEcCtD
Doxylamine—Hypersensitivity—Ifosfamide—testicular cancer	0.00178	0.00178	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00177	0.00177	CcSEcCtD
Doxylamine—Asthenia—Ifosfamide—testicular cancer	0.00173	0.00173	CcSEcCtD
Doxylamine—Sweating—Methotrexate—testicular cancer	0.00172	0.00172	CcSEcCtD
Doxylamine—Feeling abnormal—Cisplatin—testicular cancer	0.00171	0.00171	CcSEcCtD
Doxylamine—Pruritus—Ifosfamide—testicular cancer	0.00171	0.00171	CcSEcCtD
Doxylamine—Pancreatitis—Doxorubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Doxylamine—Dyspnoea—Etoposide—testicular cancer	0.0017	0.0017	CcSEcCtD
Doxylamine—Somnolence—Etoposide—testicular cancer	0.00169	0.00169	CcSEcCtD
Doxylamine—Nausea—Bleomycin—testicular cancer	0.00168	0.00168	CcSEcCtD
Doxylamine—Drowsiness—Epirubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Doxylamine—Vomiting—Dactinomycin—testicular cancer	0.00167	0.00167	CcSEcCtD
Doxylamine—Agranulocytosis—Methotrexate—testicular cancer	0.00167	0.00167	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Doxylamine—Rash—Dactinomycin—testicular cancer	0.00166	0.00166	CcSEcCtD
Doxylamine—Decreased appetite—Etoposide—testicular cancer	0.00166	0.00166	CcSEcCtD
Doxylamine—Diarrhoea—Ifosfamide—testicular cancer	0.00165	0.00165	CcSEcCtD
Doxylamine—Pancytopenia—Doxorubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00164	0.00164	CcSEcCtD
Doxylamine—Fatigue—Etoposide—testicular cancer	0.00164	0.00164	CcSEcCtD
Doxylamine—Constipation—Etoposide—testicular cancer	0.00163	0.00163	CcSEcCtD
Doxylamine—Hepatitis—Methotrexate—testicular cancer	0.00161	0.00161	CcSEcCtD
Doxylamine—Sweating—Epirubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Doxylamine—Dizziness—Ifosfamide—testicular cancer	0.00159	0.00159	CcSEcCtD
Doxylamine—Urinary tract disorder—Methotrexate—testicular cancer	0.00159	0.00159	CcSEcCtD
Doxylamine—Urethral disorder—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Doxylamine—Feeling abnormal—Etoposide—testicular cancer	0.00157	0.00157	CcSEcCtD
Doxylamine—Nausea—Dactinomycin—testicular cancer	0.00156	0.00156	CcSEcCtD
Doxylamine—Agranulocytosis—Epirubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Doxylamine—Drowsiness—Doxorubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Doxylamine—Vomiting—Ifosfamide—testicular cancer	0.00153	0.00153	CcSEcCtD
Doxylamine—Hypersensitivity—Cisplatin—testicular cancer	0.00153	0.00153	CcSEcCtD
Doxylamine—Bradycardia—Epirubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Doxylamine—Rash—Ifosfamide—testicular cancer	0.00152	0.00152	CcSEcCtD
Doxylamine—Dermatitis—Ifosfamide—testicular cancer	0.00152	0.00152	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—testicular cancer	0.00152	0.00152	CcSEcCtD
Doxylamine—Urticaria—Etoposide—testicular cancer	0.00151	0.00151	CcSEcCtD
Doxylamine—Hepatitis—Epirubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—testicular cancer	0.0015	0.0015	CcSEcCtD
Doxylamine—Asthenia—Cisplatin—testicular cancer	0.00149	0.00149	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—testicular cancer	0.00149	0.00149	CcSEcCtD
Doxylamine—Sweating—Doxorubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Doxylamine—Urinary tract disorder—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Doxylamine—Urethral disorder—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—testicular cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—testicular cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Agranulocytosis—Doxorubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Nausea—Ifosfamide—testicular cancer	0.00143	0.00143	CcSEcCtD
Doxylamine—Diarrhoea—Cisplatin—testicular cancer	0.00142	0.00142	CcSEcCtD
Doxylamine—Erythema multiforme—Epirubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Doxylamine—Bradycardia—Doxorubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Doxylamine—Eye disorder—Epirubicin—testicular cancer	0.0014	0.0014	CcSEcCtD
Doxylamine—Hypersensitivity—Etoposide—testicular cancer	0.0014	0.0014	CcSEcCtD
Doxylamine—Erythema—Methotrexate—testicular cancer	0.0014	0.0014	CcSEcCtD
Doxylamine—Cardiac disorder—Epirubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Doxylamine—Flushing—Epirubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Doxylamine—Hepatitis—Doxorubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Doxylamine—Urinary tract disorder—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Doxylamine—Asthenia—Etoposide—testicular cancer	0.00137	0.00137	CcSEcCtD
Doxylamine—Urethral disorder—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Doxylamine—Immune system disorder—Epirubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Doxylamine—Mediastinal disorder—Epirubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Doxylamine—Pruritus—Etoposide—testicular cancer	0.00135	0.00135	CcSEcCtD
Doxylamine—Vomiting—Cisplatin—testicular cancer	0.00132	0.00132	CcSEcCtD
Doxylamine—Erythema multiforme—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Doxylamine—Rash—Cisplatin—testicular cancer	0.00131	0.00131	CcSEcCtD
Doxylamine—Dermatitis—Cisplatin—testicular cancer	0.00131	0.00131	CcSEcCtD
Doxylamine—Erythema—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Doxylamine—Diarrhoea—Etoposide—testicular cancer	0.0013	0.0013	CcSEcCtD
Doxylamine—Eye disorder—Doxorubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Doxylamine—Cardiac disorder—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Doxylamine—Flushing—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Doxylamine—Malaise—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Doxylamine—Dizziness—Etoposide—testicular cancer	0.00126	0.00126	CcSEcCtD
Doxylamine—Muscle spasms—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Doxylamine—Immune system disorder—Doxorubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Doxylamine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—testicular cancer	0.00125	0.00125	CcSEcCtD
Doxylamine—Nausea—Cisplatin—testicular cancer	0.00124	0.00124	CcSEcCtD
Doxylamine—Ill-defined disorder—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—testicular cancer	0.00121	0.00121	CcSEcCtD
Doxylamine—Vomiting—Etoposide—testicular cancer	0.00121	0.00121	CcSEcCtD
Doxylamine—Erythema—Doxorubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Doxylamine—Agitation—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Doxylamine—Rash—Etoposide—testicular cancer	0.0012	0.0012	CcSEcCtD
Doxylamine—Dermatitis—Etoposide—testicular cancer	0.0012	0.0012	CcSEcCtD
Doxylamine—Malaise—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—testicular cancer	0.00118	0.00118	CcSEcCtD
Doxylamine—Vertigo—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Doxylamine—Leukopenia—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Doxylamine—Muscle spasms—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Doxylamine—Palpitations—Epirubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Doxylamine—Confusional state—Methotrexate—testicular cancer	0.00115	0.00115	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Doxylamine—Convulsion—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Doxylamine—Nausea—Etoposide—testicular cancer	0.00113	0.00113	CcSEcCtD
Doxylamine—Ill-defined disorder—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—testicular cancer	0.00112	0.00112	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—testicular cancer	0.00112	0.00112	CcSEcCtD
Doxylamine—Agitation—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Doxylamine—Anxiety—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Doxylamine—Discomfort—Epirubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Doxylamine—Malaise—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Doxylamine—Dry mouth—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Doxylamine—Vertigo—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Doxylamine—Leukopenia—Doxorubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Doxylamine—Confusional state—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Doxylamine—Palpitations—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Doxylamine—Anaphylactic shock—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Doxylamine—Convulsion—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Doxylamine—Nervous system disorder—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Doxylamine—Thrombocytopenia—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Doxylamine—Tachycardia—Epirubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Doxylamine—Hyperhidrosis—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Doxylamine—Anxiety—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Doxylamine—Discomfort—Doxorubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Doxylamine—Anorexia—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—testicular cancer	0.00101	0.00101	CcSEcCtD
Doxylamine—Dry mouth—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Doxylamine—Hypotension—Epirubicin—testicular cancer	0.000998	0.000998	CcSEcCtD
Doxylamine—Confusional state—Doxorubicin—testicular cancer	0.000996	0.000996	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—testicular cancer	0.000992	0.000992	CcSEcCtD
Doxylamine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000988	0.000988	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000985	0.000985	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—testicular cancer	0.000984	0.000984	CcSEcCtD
Doxylamine—Nervous system disorder—Doxorubicin—testicular cancer	0.000969	0.000969	CcSEcCtD
Doxylamine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000967	0.000967	CcSEcCtD
Doxylamine—Insomnia—Epirubicin—testicular cancer	0.000966	0.000966	CcSEcCtD
Doxylamine—Tachycardia—Doxorubicin—testicular cancer	0.000964	0.000964	CcSEcCtD
Doxylamine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000955	0.000955	CcSEcCtD
Doxylamine—Dyspnoea—Epirubicin—testicular cancer	0.000952	0.000952	CcSEcCtD
Doxylamine—Somnolence—Epirubicin—testicular cancer	0.000949	0.000949	CcSEcCtD
Doxylamine—Anorexia—Doxorubicin—testicular cancer	0.000942	0.000942	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—testicular cancer	0.00094	0.00094	CcSEcCtD
Doxylamine—Decreased appetite—Epirubicin—testicular cancer	0.000928	0.000928	CcSEcCtD
Doxylamine—Hypotension—Doxorubicin—testicular cancer	0.000923	0.000923	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000922	0.000922	CcSEcCtD
Doxylamine—Fatigue—Epirubicin—testicular cancer	0.000921	0.000921	CcSEcCtD
Doxylamine—Constipation—Epirubicin—testicular cancer	0.000913	0.000913	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—testicular cancer	0.000906	0.000906	CcSEcCtD
Doxylamine—Insomnia—Doxorubicin—testicular cancer	0.000894	0.000894	CcSEcCtD
Doxylamine—Dyspnoea—Doxorubicin—testicular cancer	0.000881	0.000881	CcSEcCtD
Doxylamine—Feeling abnormal—Epirubicin—testicular cancer	0.00088	0.00088	CcSEcCtD
Doxylamine—Somnolence—Doxorubicin—testicular cancer	0.000878	0.000878	CcSEcCtD
Doxylamine—Decreased appetite—Doxorubicin—testicular cancer	0.000859	0.000859	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000853	0.000853	CcSEcCtD
Doxylamine—Fatigue—Doxorubicin—testicular cancer	0.000852	0.000852	CcSEcCtD
Doxylamine—Urticaria—Epirubicin—testicular cancer	0.000848	0.000848	CcSEcCtD
Doxylamine—Constipation—Doxorubicin—testicular cancer	0.000845	0.000845	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—testicular cancer	0.000841	0.000841	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—testicular cancer	0.000819	0.000819	CcSEcCtD
Doxylamine—Feeling abnormal—Doxorubicin—testicular cancer	0.000814	0.000814	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—testicular cancer	0.000807	0.000807	CcSEcCtD
Doxylamine—Hypersensitivity—Epirubicin—testicular cancer	0.000787	0.000787	CcSEcCtD
Doxylamine—Urticaria—Doxorubicin—testicular cancer	0.000785	0.000785	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—testicular cancer	0.000781	0.000781	CcSEcCtD
Doxylamine—Asthenia—Epirubicin—testicular cancer	0.000766	0.000766	CcSEcCtD
Doxylamine—Pruritus—Epirubicin—testicular cancer	0.000755	0.000755	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—testicular cancer	0.000754	0.000754	CcSEcCtD
Doxylamine—Diarrhoea—Epirubicin—testicular cancer	0.000731	0.000731	CcSEcCtD
Doxylamine—Hypersensitivity—Doxorubicin—testicular cancer	0.000728	0.000728	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—testicular cancer	0.000725	0.000725	CcSEcCtD
Doxylamine—Rash—Methotrexate—testicular cancer	0.000719	0.000719	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—testicular cancer	0.000719	0.000719	CcSEcCtD
Doxylamine—Asthenia—Doxorubicin—testicular cancer	0.000709	0.000709	CcSEcCtD
Doxylamine—Dizziness—Epirubicin—testicular cancer	0.000706	0.000706	CcSEcCtD
Doxylamine—Pruritus—Doxorubicin—testicular cancer	0.000699	0.000699	CcSEcCtD
Doxylamine—Vomiting—Epirubicin—testicular cancer	0.000679	0.000679	CcSEcCtD
Doxylamine—Nausea—Methotrexate—testicular cancer	0.000678	0.000678	CcSEcCtD
Doxylamine—Diarrhoea—Doxorubicin—testicular cancer	0.000676	0.000676	CcSEcCtD
Doxylamine—Rash—Epirubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Doxylamine—Dermatitis—Epirubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Doxylamine—Dizziness—Doxorubicin—testicular cancer	0.000653	0.000653	CcSEcCtD
Doxylamine—Nausea—Epirubicin—testicular cancer	0.000634	0.000634	CcSEcCtD
Doxylamine—Vomiting—Doxorubicin—testicular cancer	0.000628	0.000628	CcSEcCtD
Doxylamine—Rash—Doxorubicin—testicular cancer	0.000623	0.000623	CcSEcCtD
Doxylamine—Dermatitis—Doxorubicin—testicular cancer	0.000622	0.000622	CcSEcCtD
Doxylamine—Nausea—Doxorubicin—testicular cancer	0.000587	0.000587	CcSEcCtD
